LENZ Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LENZ | YDES | LONA | SRZN | ZNTL | SER | |
|---|---|---|---|---|---|---|
| Market cap | 108.71M | 492.28M | 43.01M | 553.72M | 172.69M | 42.93M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.9 | — | — | -7.6 | -1.0 | -1.6 |
| Price/book | 0.6 | 110.3 | 1.3 | -1.7 | 0.9 | 2.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −83.70% | −39.33% | +13.84% | +142.51% | +32.84% | −58.98% |
| Today | −1.14% | +7.84% | −4.30% | +5.08% | −1.12% | −7.65% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LENZ news ›Lenz Therapeutics Reports Q3 Results and CEO Transition | VM
SAN DIEGO, Calif.—Lenz Therapeutics, Inc. (Nasdaq: LENZ), a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, an aceclidine-based eye drop for the treatment of presbyopia, has reported…
LENZ Therapeutics Q3 Earnings Call Highlights
Posted by Danessa Lincoln on Oct 31st, 2026 LENZ Therapeutics (NASDAQ:LENZ) reported third-quarter 2026 product revenue of $2.6 million, up 50% sequentially, as prescriptions for its presbyopia eye drop VIZZ increased following the…
More from 1 other outlet
Lenz targets $70M-$75M 2027 opex as it restructures to a consumer-led model and plans ~40 employees
LENZ Therapeutics Q3 2026 earnings: revenue and scripts jumped on telehealth and TV ads as it restructures amid a CEO change. Earnings Call Insights: LENZ Therapeutics (LENZ) Q3 2026 “In the third quarter, we saw more than 50% growth in…
LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increases Strategic reorganization to prioritize consumer marketing, support the…
LENZ Therapeutics, Inc. Announces CEO Changes, Effective December 1, 2026
On October 28, 2026, LENZ Therapeutics, Inc. announced that Evert Schimmelpennink, the Company?s President and Chief Executive Officer , will transition from his roles as President and CEO effective... On October 28, 2026, LENZ…
LENZ Therapeutics, Inc. Decreases Headcount By Approximately 75% To Approximately 40 Full-Time Employees
On October 28, 2026, the board of directors of LENZ Therapeutics, Inc. approved a strategic reorganization to prioritize consumer marketing, allocate capital to maximize sales growth, and reduce... On October 28, 2026, the board of…
LENZ Therapeutics, Inc.(NasdaqGS: LENZ) added to Russell 3000E Value Benchmark
LENZ Therapeutics, Inc. added to Russell 3000E Value Benchmark... Biotechnology & Medical Research LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to Russell 3000E Value Benchmark Latest news about LENZ Therapeutics, Inc. Chart LENZ…
LENZ Therapeutics GAAP EPS of -$0.99 misses by $0.04, revenue of $3.38M misses by $0.82M
LENZ Therapeutics Q3 earnings missed on EPS and revenue, with sales down 73% year over year. - LENZ Therapeutics press release (LENZ): Q3 GAAP EPS of -$0.99 misses by $0.04. - Revenue of $3.38M (-73.0% Y/Y) misses by $0.82M. More on LENZ…
Contrasting Sunshine Biopharma (NASDAQ:SBFM) and LENZ Therapeutics (NASDAQ:LENZ)
Posted by Danessa Lincoln on Oct 26th, 2026 LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) and Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
Lenz Therapeutics price target lowered to $50 from $60 at TD Cowen
TD Cowen analyst Stacy Ku lowered the firm’s price target on Lenz Therapeutics (LENZ) to $50 from $60 and keeps a Buy rating on the shares.The f... Lenz Therapeutics price target lowered to $50 from $60 at TD Cowen TD Cowen analyst Stacy…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- seekingalpha.com6
- marketscreener.com5
- markets.businessinsider.com4
- themarketsdaily.com2
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 20 articles, not a forecast.